No OS Benefits with Addition of Perifosine to Capecitabine in mCRC
Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.